111Indium-trastuzumab visualises myocardial human epidermal growth factor receptor 2 expression shortly after anthracycline treatment but not during heart failure: A clue to uncover the mechanisms of trastuzumab-related cardiotoxicity
- 30 September 2007
- journal article
- Published by Elsevier BV in European Journal of Cancer
- Vol. 43 (14), 2046-2051
- https://doi.org/10.1016/j.ejca.2007.06.024
Abstract
No abstract availableThis publication has 16 references indexed in Scilit:
- Herceptin and the Heart — A Molecular Modifier of Cardiac FailureThe New England Journal of Medicine, 2006
- Adjuvant Docetaxel or Vinorelbine with or without Trastuzumab for Breast CancerThe New England Journal of Medicine, 2006
- Reversibility of Trastuzumab-Related Cardiotoxicity: New Insights Based on Clinical Course and Response to Medical TreatmentJournal of Clinical Oncology, 2005
- Assessment of Cardiac Dysfunction in a Randomized Trial Comparing Doxorubicin and Cyclophosphamide Followed by Paclitaxel, With or Without Trastuzumab As Adjuvant Therapy in Node-Positive, Human Epidermal Growth Factor Receptor 2–Overexpressing Breast Cancer: NSABP B-31Journal of Clinical Oncology, 2005
- Trastuzumab plus Adjuvant Chemotherapy for Operable HER2-Positive Breast CancerThe New England Journal of Medicine, 2005
- Trastuzumab after Adjuvant Chemotherapy in HER2-Positive Breast CancerThe New England Journal of Medicine, 2005
- Type II Chemotherapy-Related Cardiac Dysfunction: Time to Recognize a New EntityJournal of Clinical Oncology, 2005
- Cardiac Endothelial Cells Regulate Reactive Oxygen Species-induced Cardiomyocyte Apoptosis through Neuregulin-1β/erbB4 SignalingJournal of Biological Chemistry, 2004
- Use of Chemotherapy plus a Monoclonal Antibody against HER2 for Metastatic Breast Cancer That Overexpresses HER2The New England Journal of Medicine, 2001
- Doxorubicin-Induced CardiomyopathyThe New England Journal of Medicine, 1998